News >

Expert Discusses Durvalumab and Expanding Role of Immunotherapy in NSCLC

Angelica Welch
Published: Thursday, Nov 09, 2017

Marina Chiara Garassino, MD

Marina Chiara Garassino, MD
The treatment landscape of non–small cell lung cancer (NSCLC) has had a number of encouraging findings in the last 3 years, particularly with checkpoint inhibitors that target the PD-1/PD-L1 pathway.

Marina C. Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discussed the evolving paradigm of immunotherapy in NSCLC, with a specific focus on durvalumab and the role of combination therapy.

OncLive: What is the current role of immunotherapy in lung cancer?

Garassino: In the last 3 years, there was a big change in the paradigm of cancer care with immunotherapy. With the advance of immunotherapy now, we’ve changed the paradigm in several points of disease in patients with NSCLC, starting from stage III disease—which is the big novelty of this year with the PACIFIC trial. We also have several new drugs for the first-line treatment, in particular for patients with PD-L1 expression. The survival of patients treated with pembrolizumab (Keytruda) presented [at the IASLC 18th World Conference on Lung Cancer], was 30 months. Before it was about 17 months, so it really has radically changed the treatment of NSCLC.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication